Multiclass Machine Learning-Based Discovery of Novel Scaffold Inhibitors Targeting ALK
Pharmaceuticals · 2026-08-01 · 19 (8) · 1209
DOI: 10.3390/ph19081209 ↗At a glance
Journal article in Pharmaceuticals, published online on 2026-08-01. Written by Md Azizul Haque and 7 co-authors. Institution: Department of Biotechnology, Yeungnam University, Gyeongsan 38541, Republic of Korea. 62 references. The full text is freely available (open access, CC BY 4.0). Funded by: Princess Nourah bint Abdulrahman University.
Abstract (original language)
Background
Anaplastic Lymphoma Kinase (ALK) is an oncogenic receptor tyrosine kinase implicated in several cancers. Despite the clinical success of ALK inhibitors, acquired resistance continues to drive the search for novel chemotypes. We developed a multiclass machine learning framework to classify ALK inhibitory activity using a curated ChEMBL dataset.
Methods
Models were built using 2D molecular descriptors together with MACCS and ECFP4 fingerprints. Three widely used algorithms, Support Vector Machine (SVM), Random Forest (RF), and XGBoost, were applied for model development.
Results
RF and XGBoost models demonstrated the best performance, achieving accuracies of ~0.75–0.79 with consistently high ROC–AUC values, particularly for fingerprint-based features. Bemis–Murcko scaffold analysis identified enriched chemotypes and underexplored scaffolds for further prioritization. The validated models were subsequently used to screen the Maybridge library, and compounds predicted to possess potential ALK inhibitory activity were prioritized for further computational evaluation. Applicability-domain filtering confirmed that the selected compounds occupied the predicted ALK inhibitor chemical space across multiple activity classes. The shortlisted compounds were subsequently evaluated by molecular docking to characterize their binding modes and interactions. Three candidate hits (SCR00078, SCR00073, and AW01085) were selected for further evaluation using 500 ns molecular dynamics simulations alongside the reference inhibitor Brigatinib. Simulation analyses revealed stable protein–ligand complexes and reduced conformational fluctuations relative to apo ALK, while MM/PBSA calculations identified SCR00078 and AW01085 as the most favorable binders.
Conclusions
This integrated ML-to-simulation workflow prioritizes structurally novel candidate hits with predicted ALK inhibitory activity and provides an effective strategy for scaffold discovery and hit prioritization.
Subjects
Author keywords
Authors and institutions
- Department of Biotechnology, Yeungnam University, Gyeongsan 38541, Republic of Korea.
- Department of Health Informatics, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.
- Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh 11671, Saudi Arabia.
- Department of Biology, College of Sciences, University of Hail, Hail 55476, Saudi Arabia.
ORCID profiles: Md Azizul Haque, Qazi Mohammad Sajid Jamal, Khurshid Ahmad, Reem Binsuwaidan, Mohd Saeed
Funding
- Princess Nourah bint Abdulrahman University
Cite
APA
Haque, M. A., Jamal, Q. M. S., Ahmad, K., Binsuwaidan, R., Alshammari, N., Saeed, M., Kim, J. J., & Danishuddin (2026). Multiclass Machine Learning-Based Discovery of Novel Scaffold Inhibitors Targeting ALK. Pharmaceuticals, 19(8), 1209. https://doi.org/10.3390/ph19081209
Vancouver
Haque MA, Jamal QMS, Ahmad K, Binsuwaidan R, Alshammari N, Saeed M, et al. Multiclass Machine Learning-Based Discovery of Novel Scaffold Inhibitors Targeting ALK. Pharmaceuticals. 2026;19(8):1209. doi:10.3390/ph19081209
BibTeX
@article{Haque2026,
author = {Haque, Md Azizul and Jamal, Qazi Mohammad Sajid and Ahmad, Khurshid and Binsuwaidan, Reem and Alshammari, Nawaf and Saeed, Mohd and Kim, Jong-Joo and Danishuddin},
title = {Multiclass Machine Learning-Based Discovery of Novel Scaffold Inhibitors Targeting ALK},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {8},
pages = {1209},
doi = {10.3390/ph19081209}
}
EUVIMED